Quantcast

Latest Low-density lipoprotein Stories

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

Winter's Cold May Lead To Higher Cholesterol Levels: Study
2014-03-28 12:02:26

Brett Smith for redOrbit.com - Your Universe Online Past research has shown that heart attacks and heart-related deaths rise during the winter months and researchers at Johns Hopkins Ciccarone Center for the Prevention of Heart Disease recently found that increased cholesterol levels may be to blame. The new study, which is being presented at the American College of Cardiology's 63rd Annual Scientific Session in Washington, DC this week, is based on cholesterol parameters among a sample...

2014-03-27 04:20:44

Companies to Host Investor Conference Call on Alirocumab on March 31 at 9 AM EDT PARIS and TARRYTOWN, N.Y., March 27, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from alirocumab clinical studies will be presented at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, D.C. March 29-31. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein...

2014-03-24 20:23:34

Five Phase 3 Studies With Evolocumab (AMG 145) to be Featured in Late-Breaking and Clinical Research Presentations - Data Form the Basis of Global Filing Plan THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density...

2014-03-19 08:28:25

CARLSBAD, Calif., March 19, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-ANGPTL3(Rx), an antisense drug targeting angiopoietin-like 3 protein (ANGPTL3), an independent risk factor for cardiovascular disease. ISIS-ANGPTL3(Rx) is designed to act as a broad dyslipidemia agent. By reducing ANGPTL3, ISIS-ANGPTL3(Rx) has the potential to reduce LDL-cholesterol and triglycerides, and to increase...

2014-03-17 08:30:17

Study Meets Primary Endpoint of LDL Cholesterol Reduction THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C). The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful and statistically...

2014-03-14 20:21:47

WOODBRIDGE, ON, March 14, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in...

2014-03-13 23:02:07

Center for Primary Care participates in and sponsors the CSRA Heart Walk, raising awareness for cardiovascular disease and heart health. Evans, GA (PRWEB) March 13, 2014 Center for Primary Care recently participated in and sponsored the CSRA Heart Walk. The walk took place at 8:30 a.m. March 8 and raised awareness for cardiovascular disease and heart health. Center for Primary Care was on hand at the walk to offer tips and information for maintaining a healthy heart. Cardiovascular...

2014-03-03 23:01:45

Kyowa Hakko USA announces that Pantesin is a comprehensive and safe dietary supplement that supports healthy cholesterol levels. New York, NY (PRWEB) March 03, 2014 A recently published study in Vascular Health and Risk Management showed that Pantesin® Pantethine was effective in lowering cardiovascular risk markers in study participants with low to moderate risk factors who were eligible for statin therapy. Specifically when compared to placebo, Pantesin showed significant changes...

Adding More Fish To Your Diet Can Increase Good Cholesterol
2014-03-03 12:49:29

Lee Rannals for redOrbit.com - Your Universe Online Adding more fish to your diet could help boost good cholesterol levels, according to a new study published in PLOS ONE. Scientists at the University of Eastern Finland found that people who increase their intake of fish to a minimum of three to four fatty fish servings per week could increase the number of HDL particles in their blood, which are believed to protect against cardiovascular diseases. Although many studies have been...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related